ASSOCIATION BETWEEN CYP2C9 PROMOTER REGION VARIANTS AND WARFARIN DOSE REQUIREMENTS IN AFRICAN AMERICANS.

被引：0
|
作者：
Cavallari, L. [1 ]
Drozda, K. [1 ]
Perera, M. [2 ]
Patel, S. [1 ]
Shapiro, N. [1 ]
Nutescu, E. [1 ]
Stamos, T. [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 50 条
  • [31] Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients
    Spreafico, M
    Peyvandi, F
    Pizzotti, D
    Moia, M
    Mannucci, PM
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (10) : 2252 - 2253
  • [32] Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis
    Jonatan D. Lindh
    Lennart Holm
    Marine L. Andersson
    Anders Rane
    European Journal of Clinical Pharmacology, 2009, 65 : 365 - 375
  • [33] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    G. Oner Ozgon
    T. Y. Langaee
    H. Feng
    N. Buyru
    T. Ulutin
    A. C. Hatemi
    A. Siva
    S. Saip
    J. A. Johnson
    European Journal of Clinical Pharmacology, 2008, 64 : 889 - 894
  • [34] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    Ozgon, G. Oner
    Langaee, T. Y.
    Feng, H.
    Buyru, N.
    Ulutin, T.
    Hatemi, A. C.
    Siva, A.
    Saip, S.
    Johnson, J. A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 889 - 894
  • [35] THE IMPACT OF CYP2C9 AND VKORC1 VARIANTS ON STABLE WARFARIN DOSE IN THE PEDIATRIC POPULATION
    Vear, Susan
    Ayers, Dan
    Stein, C. Michael
    Ho, Richard
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S34 - S35
  • [36] The influence of coagulation factor and CYP2C9 polymorphisms on warfarin dose
    Aquilante, CL
    Yarandi, HN
    Langaee, TY
    Tromberg, JS
    Lopez, LM
    Waddell, CD
    Johnson, JA
    CIRCULATION, 2003, 108 (17) : 424 - 424
  • [37] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism
    King, BP
    Khan, TI
    Kamali, F
    Daly, AK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 639 - 639
  • [38] Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms
    Mark W. Linder
    Stephen Looney
    Jesse E. Adams
    Nancy Johnson
    Deborah Antonino-Green
    Nichole Lacefield
    Bonny L. Bukaveckas
    Roland Valdes
    Journal of Thrombosis and Thrombolysis, 2002, 14 : 227 - 232
  • [39] Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
    Linder, MW
    Looney, S
    Adams, JE
    Johnson, N
    Antonino-Green, D
    Lacefield, N
    Bukaveckas, BL
    Valdes, R
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2002, 14 (03) : 227 - 232
  • [40] Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9
    Khaleqsefat, E.
    Khalaj-Kondori, M.
    Bonyadi, Jabbarpour M.
    Battaloglu, E.
    HIPPOKRATIA, 2017, 21 (02) : 93 - 96
12345